Investing Profile

Jim Tananbaum

VCInvestorCEOFounder

Founder and CEO at Foresite Capital Management

foresitecapital.com/people/ji...San Francisco, California

Your Intro Paths to Jim Tananbaum

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Jim is a member of

Hotmail Network

5844 CONNECTIONS

Harvard Business School Network

824 CONNECTIONS

Massachusetts Institute of Technology Network

628 CONNECTIONS

Massachusetts Institute of Technology Network

628 CONNECTIONS

Yale University Network

415 CONNECTIONS

Find Jim Tananbaum on

Current Investing Position

Foresite Capital Management

Investment Range

$100K - $5.0M

Sweet Spot

$1.5M

Investments On Record

Jim Tananbaum is on these Sector & Stage Rankings

Consumer Health (Series B)BioTech (Series B)Consumer Health (Series A)BioTech (Seed)Consumer Health (Seed)BioTech (Series A)Health IT (Series A)Health & Hospital Services (Series B)Health & Hospital Services (Series A)San Francisco Bay Area Digital Health (Series B)Health IT (Seed)Health IT (Series B)Digital Health (Series A)Digital Health (Seed)Health & Hospital Services (Seed)

Jim Tananbaum's Investments On Record (23)

Company	StageDateRound Size	Total Raised
Foresight Diagnostics	Series BJul 2024$33M Series BApr 2023$59M	$110M
Co-investors: Shahram Seyedin-Noor (Civilization Ventures), Vikram Bajaj (Foresite Capital)
Element Biosciences	Series DJul 2024$280M Series CJun 2021$280M	$550M
Co-investors: Bryan Roberts (Venrock)
Alumis	Series CMar 2024$260M Series AMay 2021$70M	$330M
Co-investors: Michael Rome (Foresite Capital), Vikram Bajaj (Foresite Capital), Richard Gaster (venBio Partners)
Genomics	Series CJan 2024$45M Series UnknownMar 2021$30M	$84M
Co-investors: Stephen Knight (F-Prime Capital (formerly Fidelity Biosciences))
evonetix	Series BFeb 2023$24M Series BMar 2020$30M	$66M
Co-investors: Armen Vidian (DCVC (Data Collective)), Ameena El-Bibany (Artis Ventures (AV)), Vishal Gulati (Molten Ventures)
DNAnexus	Series HMar 2022$200M Series GJun 2020$100M Series FFeb 2019$68M Series EJan 2018$58M	$460M
Co-investors: Jeff Clavier (Uncork Capital), Krishna Yeshwant (GV (Google Ventures)), Manu Kumar (K9 Ventures), Rob Hayes (First Round Capital), Michael Rubin (Sands Capital Ventures), Nat Goldhaber
ImmPACT Bio	Series BJan 2022$140M	$140M
Co-investors: Cindy Xiong (Venrock), Yvonne Yamanaka (venBio Partners), Richard Gaster (venBio Partners)
XinThera	Series BAug 2021$50M	$50M
Co-investors: Carl Gordon (OrbiMed Advisors), Michael Rome (Foresite Capital)

Jim Tananbaum's Experience

Product Manager, Prilosec MerckPresent

Co-Founder. Board Member. HotmailPresent

Co-Founder. Board Member. GelTex (acquired Genzyme $1.6 B)Present

Partner SIERRA VenturesPresent

Co-Founder and Chief Executive Officer Theravance Biopharma US, LLCPresent

Founder and CEO Foresite CapitalPresent

Co-Founder and Chief Executive Officer Theravance (THRX)Present

Co-Founder and Managing Director PVP2 & PVP3 Prospect Venture PartnersPresent

Founder and CEO Foresite Capital ManagementPresent

Partner Sierra Ventures1993 - 1997

Co-Founder and CEO GelTex (acquired by Genzyme for $1.6 B)1991 - 1992

Jim Tananbaum's Education

Harvard Business School mba

Harvard Medical School Doctor of Medicine (MD)

Massachusetts Institute of Technology Master of Science (M.S.) HST - information theory

Yale University BS BSEE, Math, computer science

Yale University BS, BSEE Math, computer science

Yale University BS BSEE, Applied Math, Electrical Engineering/Computer Science

Yale University BS, BSEE Applied Math, Electrical Engineering/Computer Science

Harvard Medical School Doctoral Affiliation Health, Science, and Technology

Massachusetts Institute of Technology Doctoral Affiliation Health, Science, and Technology

Investors who invest with Jim Tananbaum

Scouts & Angels Affiliated With Jim Tananbaum